JP2010529999A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529999A5
JP2010529999A5 JP2010512385A JP2010512385A JP2010529999A5 JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5 JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010512385 A JP2010512385 A JP 2010512385A JP 2010529999 A5 JP2010529999 A5 JP 2010529999A5
Authority
JP
Japan
Prior art keywords
composition
polysorbate
phosphate buffer
sodium chloride
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/066928 external-priority patent/WO2008157356A2/en
Publication of JP2010529999A publication Critical patent/JP2010529999A/ja
Publication of JP2010529999A5 publication Critical patent/JP2010529999A5/ja
Pending legal-status Critical Current

Links

JP2010512385A 2007-06-14 2008-06-13 抗体製剤 Pending JP2010529999A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94407607P 2007-06-14 2007-06-14
PCT/US2008/066928 WO2008157356A2 (en) 2007-06-14 2008-06-13 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013182749A Division JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Publications (2)

Publication Number Publication Date
JP2010529999A JP2010529999A (ja) 2010-09-02
JP2010529999A5 true JP2010529999A5 (enExample) 2011-07-28

Family

ID=39956053

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010512385A Pending JP2010529999A (ja) 2007-06-14 2008-06-13 抗体製剤
JP2013182749A Pending JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013182749A Pending JP2014040424A (ja) 2007-06-14 2013-09-04 抗体製剤

Country Status (24)

Country Link
US (3) US20080311119A1 (enExample)
EP (2) EP2170390B1 (enExample)
JP (2) JP2010529999A (enExample)
CN (2) CN101778640A (enExample)
AR (2) AR067011A1 (enExample)
AU (1) AU2008266051B2 (enExample)
BR (1) BRPI0814252B8 (enExample)
CA (1) CA2690382A1 (enExample)
CY (1) CY1121208T1 (enExample)
DK (1) DK2170390T3 (enExample)
EA (1) EA020456B1 (enExample)
ES (1) ES2707815T3 (enExample)
HR (1) HRP20182146T1 (enExample)
HU (1) HUE041555T2 (enExample)
IL (1) IL202648B (enExample)
LT (1) LT2170390T (enExample)
MX (2) MX2009013593A (enExample)
NZ (2) NZ595526A (enExample)
PL (1) PL2170390T3 (enExample)
PT (1) PT2170390T (enExample)
SI (1) SI2170390T1 (enExample)
TR (1) TR201820837T4 (enExample)
TW (1) TWI614028B (enExample)
WO (1) WO2008157356A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
US20120183531A1 (en) * 2009-07-14 2012-07-19 Biogen Idee Ma Inc Methods for Inhibiting Yellow Color Formation in a Composition
CN107496917B (zh) 2010-02-26 2021-06-11 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
SG183443A1 (en) 2010-03-01 2012-09-27 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
HUE050858T2 (hu) 2010-04-16 2021-01-28 Biogen Ma Inc VLA-4 ellenes antitestek
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
WO2013006461A1 (en) * 2011-07-01 2013-01-10 Biogen Idec Ma Inc. Cholesterol-based media supplementals for cell culture
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
CN104011073B (zh) 2011-10-18 2017-08-25 科荣生生物科学公司 使用氨基酸稳定的依那西普制剂
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
SG11201407779YA (en) * 2012-06-21 2015-02-27 Ucb Pharma Sa Pharmaceutical formulation
EP2869816A4 (en) 2012-07-09 2016-04-20 Coherus Biosciences Inc ETANERCEPT FORMULATIONS WITH CLEAR REDUCTION OF SUBVISIBLE PARTICLES
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
RS57013B1 (sr) 2012-09-11 2018-05-31 Coherus Biosciences Inc Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103217525B (zh) * 2013-03-21 2015-04-29 上海执诚生物科技股份有限公司 一种含有提高胱抑素c胶乳包被抗体的稳定性的组合物、稳定剂及其制备方法和用途
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
KR102362002B1 (ko) * 2013-11-29 2022-02-10 제넨테크, 인크. 항체 선택 장치 및 방법
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
JP2017510627A (ja) * 2014-03-13 2017-04-13 プロセナ バイオサイエンシーズ リミテッド 多発性硬化症の併用治療
EP3149030A2 (en) * 2014-06-02 2017-04-05 Laboratoire Francais du Fractionnement et des Biotechnologies Societe Anonyme Production of fc fragments
BR112017007393A2 (pt) * 2014-10-18 2017-12-19 Pfizer composições de anticorpo anti-il-7r
EP3463461A4 (en) 2016-05-27 2020-05-20 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
GB201703062D0 (en) * 2017-02-24 2017-04-12 Arecor Ltd Stabilized antibody protein solutions
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
MX2020004284A (es) 2017-10-26 2020-10-28 Alexion Pharma Inc Dosis y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (hpn) y el sindrome hemolitico uremico atipico (shua).
EP3773696A4 (en) * 2018-04-10 2021-12-29 Dr. Reddy's Laboratories Ltd. Stable formulations of therapeutic antibody
KR102848349B1 (ko) 2018-06-04 2025-08-21 바이오젠 엠에이 인코포레이티드 감소된 효과기 기능을 갖는 항-ｖｌａ-4 항체
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
AU2020310196A1 (en) * 2019-07-10 2022-01-27 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising reduced level of host cell proteins
EP4021497B1 (en) * 2019-08-30 2026-02-25 Kashiv Biosciences, LLC Novel formulation of highly concentrated pharmacologically active antibody
CN113134081A (zh) * 2020-01-20 2021-07-20 上海君实生物医药科技股份有限公司 抗btla抗体药物组合物及其用途
TW202227483A (zh) * 2020-10-30 2022-07-16 日商衛材R&D企管股份有限公司 醫藥組合物
WO2022104156A1 (en) 2020-11-14 2022-05-19 Biogen Ma Inc. Biphasic subcutaneous dosing regimens for anti-vla-4 antibodies
JP2024513974A (ja) 2021-04-13 2024-03-27 バイオジェン・エムエイ・インコーポレイテッド 慢性活動性白質病変／放射線学的孤立性症候群を治療するための組成物及び方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS62196921A (ja) 1986-02-25 1987-08-31 Nec Corp 位相検出回路
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5789650A (en) * 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP0678018B1 (en) 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CA2153692C (en) 1993-01-12 2011-11-08 Roy R. Lobb Recombinant anti-vla4 antibody molecules
ES2114183T5 (es) * 1993-02-09 2006-06-16 Biogen Idec Ma, Inc. Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
AU703152B2 (en) * 1994-01-25 1999-03-18 Biogen Ma Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
DE19541844C1 (de) * 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DE122004000004I1 (de) * 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
CA2478458A1 (en) 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
WO2006055871A2 (en) * 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Treatment for multiple sclerosis
EP2053961A4 (en) 2006-08-09 2013-05-01 Biogen Idec Inc METHOD FOR DISPENSING A MEDICAMENT

Similar Documents

Publication Publication Date Title
JP2010529999A5 (enExample)
JP2010522208A5 (enExample)
JP2011088913A5 (enExample)
JP2016513069A5 (enExample)
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
IL215275A0 (en) Pharmaceutical formulations and methods for treating respiratory tract infections
JP2012184234A5 (enExample)
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
JP2009531457A5 (enExample)
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
JP2015527402A5 (enExample)
CL2012001966A1 (es) Formulación farmacéutica que comprende entre 100-150 mg/ml de un anticuerpo que se une específicamente al receptor a de il-17 humana, una solución acuosa de un buffer 5-30 mm de ácido glutámico ph 4,5-5,2, prolina 2-4% p/v y polisorbato-20 0,005-0,02% p/v; envase farmacéutico y kit que comprende dicha formulación; y su uso para tratar psoriasis.
FI4374878T3 (fi) Karbetosiinia käsittävä farmaseuttinen koostumus
NZ597237A (en) Sublingual apomorphine
MY166045A (en) Abeta antibody formulation
HRP20150744T4 (hr) Modulatori farmakokinetičkih svojstava lijekova
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
NO20082904L (no) Feksofenadinsupensjonsformulering
JP2013510169A5 (enExample)
EP1885380A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ARSENE (III ACID), SODIUM SALT AND THEIR DERIVATIVES FOR THE TREATMENT OF UROGENITAL CANCER AND METASTASES THEREOF
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
JP2005527551A5 (enExample)
JP2016510747A5 (enExample)
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno